![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Telaprevir/Peginterferon/Ribavirin
|
|
|
Reported by Jules Levin
5th International Workshop on Hepatitis C, Resistance and New Compounds
June24-25, 2010, Boston MA
Tara L Kieffer, DJ Bartels, JC Sullivan, EZ Zhang, AM Tigges, JL Dorrian, and AD Kwong, Vertex Pharmaceuticals Incorporated, Cambridge MA, USA
"TVR should be stopped upon detection of breakthrough (stopping rules at week 4)"
![](../images/070110/070110-1/image002.gif)
1McHutchison JG, et al. N Engl J Med 2009;360:1827-1838; 2Hézode C, et al. N Engl J Med 2009;360:1839-1850
![](../images/070110/070110-1/image004.gif)
![](../images/070110/070110-1/image006.gif)
![](../images/070110/070110-1/image008.gif)
![](../images/070110/070110-1/image010.gif)
![](../images/070110/070110-1/image012.gif)
1McHutchison JG, et al. N Engl J Med 2009;360:1827-1838; 2Hézode C, et al. N Engl J Med 2009;360:1839-1850;
3McHutchison JG, et al. N EnglJ Med 2010; 362:1292-1303; 4Shiffman ML, et al. Hepatology 2008;48 (Suppl 4):1135A
![](../images/070110/070110-1/image014.gif)
"TVR should be stopped upon detection of breakthrough (stopping rules at week 4)"
![](../images/070110/070110-1/image016.gif)
![](../images/070110/070110-1/image018.gif)
![](../images/070110/070110-1/image020.gif)
![](../images/070110/070110-1/image022.gif)
![](../images/070110/070110-1/image024.gif)
![](../images/070110/070110-1/image026.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|